MYOV - Earnings call transcript Q2 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, everyone and welcome to Myovant Sciences Second Fiscal Quarter 2020 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Mr. Ryan Crowe, Vice President of Investor Relations at Myovant. Please go ahead.

Ryan Crowe

Operator. you, Thank thanks business and quarter us for today financial Good and for to general update fiscal review a results. morning joining Myovant's XXXX second

Executive Dr. Joining Officer; Financial Arjona, Interim and Seely, call Chief for Officer; Gulfo, Karbe, are Commercial Juan me Myovant's and today's Adele Chief Dr. Officer; Chief Chief Medical Frank President Lynn Camilo Officer.

presented website on press morning, the will be In our this slides available are Relations earlier addition during release to webcast issued investors.myovant.com. the Investor today's that

course from be our respect these that and the beyond call, opportunities, be these and found product During which this are of we'll plans A strategies, of materially making risks conference include control risks These latest discussion involve in and forward-looking of documents. cause SEC of certain disclosure and actual our can could candidates, uncertainties to statements. financials, statements. all expectations results differ assumptions to with our

obligation during Myovant to the to addition, In Myovant's forward-looking Dr. now Lynn? Lynn call. Chief call that, this statements turn over Seely, does I'll any update Officer. With Executive undertake not an made

Lynn Seely

transformative Thank we're first Ryan, for as importantly, progress more to-date approach and advocacy. where for men to and review women empowering everyone. Myovant, good and and we'll science, you, Today our we At medicine, commercial Myovant's care launches. we aspire headed morning redefine purpose-driven through

antagonist which prostate with and treatment evaluated endometriosis drug is day uterine with molecule being candidate GnRH relugolix, is investigational men advanced or lead receptor a small for fibroids Our women once one a as for option a cancer. pill oral

separately for formulations if relugolix two approved. developed be have We branded which distinct will

for relugolix combination our health First, women's we have indication. tablet a

and for one a to expect uterine fibroids endometriosis. single have We brand for and name dose both

we tablet positive, been each X men basis dose a forming large conducted for higher relugolix. three advanced which founding cancer, monotherapy applications. once-daily has containing new robustly prostate of Phase clinical we of with trials, Since in have drug a our five XXXX, have For multinational the

SPIRIT therapy, uterine of programs. is combination months relugolix and with two positive withdrawal program a is the X which two SPIRIT which LIBERTY study ongoing. study, LIBERTY study, of X extension a consists endometriosis The extension The ongoing. For positive program studies randomized Phase study one-year six in Phase we women have long-term a completed and consists and conducted long-term fibroids

We endometriosis. prospective also and observational in density women one-year conducted a bone study untreated uterine with have fibroids

relugolix have global men, completed For for with developing prostate study our designed we're regulatory cancer, filings. successfully monotherapy, we X HERO advanced Phase

therapeutic a uterine second with FDA candidate an Xa kisspeptin-X for underdevelopment MVT-XXX XXXX. date clinical agonist for fibroids, was year X, a given also for NDA XXXX our Myovant. review is In infertility. pivotal and have accepted been is action of Phase receptor women has We that June study. target a novel completed oligopeptide

uterine therapy in for of with XXX on fibroids bone and in one responder demonstrated in combination density women the Meeting did LIBERTY relugolix women density relugolix Reproductive treated from on women This for a average program as study, dataset criteria is the of from In experienced shown women in at the blood in year, blood Society consisting combination uterine fibroids. History also women a in We first oral at from March with Agency receive bleeding year. in during menstrual over XXXX. at European and Efficacy concurrently women heavy evaluating our study one in depicted with enrolled bone were American presented data age preservation marketing submitted but green. mineral studies, authorization from longitudinal achieved the Medicine uterine Natural evaluating Observational study with the of women XX% October. treatment. History LIBERTY enrolled loss not site menstrual Data presentation Natural safety XX% our is matched long-term orange GnRH baseline. loss reduction Medicines study, Women therapy Data extension application our reduction and fibroids prizewinning the in the in a and same the were premenopausal to menstrual

can over tablet, year a of relugolix believe uterine fibroids with best-in-class relugolix therapy see, untreated approved, you fibroids. to for be uterine the with if the symptomatic therapy millions treated women women in As with changes with women. density We in combination of consistent are potential has that one medical those combination

caution, X endometriosis severe to to in Phase women We benefits at endometriosis. minimal Data case and in safety hot but from assessment in tolerability especially bone presentation as These also our or is October. women associated and clinically measures women two replicate dysmenorrhea, during achieved Phase issues, also common best clinical moderate endometriosis moderate flashes, oral the and with with different the painful data women must a be presented to pain in columns dyspareunia endometriosis data from evaluating in Comparing density with selected slide. very of for clinical SPIRIT reduction at important particularly have with in a symptom the the positive Meeting. This pain with And the this always is Approximately a paper with combinations finding responded period. ASRM done concerning different severe in SPIRIT orange are reduction dyspareunia studies studies XX% efficacy studies for years. loss. relugolix were Annual a significant presented with meaningful X this or in XXXX their was intercourse, in

has relugolix the this relugolix We that treatment. with believe relugolix to from treatment dose that of approved, slide, other you of data believe combination a of once-daily as approved tolerability have like combination a comparable profile, safety and differentiated However, can low high relugolix. see endometriosis, to the dose profile from therapy an efficacy endometriosis of a pill poised in is the one tablet, more if for profile we

The granted from Clinical simultaneously data HERO and Oncology New Meeting cancer prostate the the at priority advanced earlier review Journal December date was in has cancer Phase an XX, X action prostate Global men target year. of advanced with and study American England this for of the NDA presented Society Medicine FDA Our XXXX. published were in of

of access business other into with we services. collaboration distribution as license well and Sumitomo including U.S. support, In a with side, development a entered commercialization into August, retail shareholder, Richter commercial Pharma, logistics, have endometriosis a to of we markets commercialize support Dainippon America. fibroids active Sunovion Gedeon the trade in entered agreement we XXXX. been combination also Latin for to including as Pharmaceuticals, March, in majority a quite and certain relugolix subsidiary the In agreement international market contracting and On uterine Europe and relugolix planned tablet

partners upcoming term million, loan from also an commitment, ultimately prepare $XXX in With reached XX the providing despite indications. the Sumitomo of far period XXXX. to Sumitomo of pandemic for were two to transformational Myovant truly posed flexibility low and potential our resource interest but million, We has all this And to Pharma. potential that itself. in to products, The additional around the has financial a fact total financing all Dainippon our right us Myovant the the dedication appropriately a relugolix the able we to with achieve commitment latest launches expected XXXX by be challenges is as we we've busy next short, launches, the the months $XXX the five-year world. progress In for Dainippon truly of of testament employees positioned support without been obtained three in these for made we milestones so have Myovant COVID-XX

the FDA our For of our uterine NDA to target forward fibroids action look XXXX. June X, program, on we date

We European for a also next from year anticipate Commission a decision Authorization Marketing Application. the

in XXXX. report randomized withdrawal from study to expect QX we results Finally, our top-line

addition we X EU endometriosis, next SPIRIT our and studies X to quarter of in of in U.S. one from this expected XXXX. regulatory and year. basis results form announce study study, plan to For the of Phase positive the to X the extension The filings long-term SPIRIT the are results first year in

if relugolix U.S. launching prostate forward FDA next in approved look we XXXX. the for in early the Finally, month advanced cancer to in and decision

We MAA XXXX. prostate the half to submit Medicines Agency also in European our advanced for cancer expect first to of

is about the made of I towards progress our couldn't months, early potential Adele this with more execution cancer has team starts Adele? the opportunity Commercial an now goal. launch highest commercial the I in pleased Myovant's our priority. indications will next be XX And As strong with discuss. commercial think prostate clearly execution XXXX

Adele Gulfo

you, Thank Lynn.

Notably, men relugolix deliver following patients. X We The for medicines. for has for to to frontline therapy launch Our enable and could team cancer. believe foundational working oncologists, to and us become prostate it other Deprivation comprehensive Therapy relugolix the with medical medical long-term prostate that and a commercial with goal There hard rapidly efficiently combination cancer developing approval in will with important used advanced with as establish urologists, alone are million their in Androgen men Of for cancer the is strategy been relugolix several than for those is of men or the a Prostate are rather approximately cardiovascular is cancer. itself. in cancer Therapy common projected prostate disease XXXX receive This options the cancer more Deprivation second in prostate advanced when the with on to Androgen therapy in treatment consider particularly patients today's majority men cancer we U.S. prostate die will prostate most years. ADT XXX,XXX remaining the U.S. cancer

Testosterone landscape. to is are few depot Now first such suppression care. used therapy leuprolide advanced as line on current ADT agonists the cancer market standard of treat current words medical prostate and injectable a the the

and However, prostate the surge action. agonist can results in of mechanism clinical injections in clinic in given of limitations on be exacerbate must based that testosterone have symptoms an Agonist cancer. their initial

can it decline. weeks addition, take In to PSA

their GnRH Finally, take are would and cancer. due for be depot after to discontinued If antagonist to agonist the injections relugolix first testosterone only approved, recover formulations. months advanced can prostate long-acting

suppressed surge suppression the addition the that once-daily In the without men and range and relugolix of sustained and tablet, flare. leuprolide target than study clinical HERO the of had did a testosterone XX% being testosterone convenience faster testosterone so that to to demonstrated

leuprolide In following normal testosterone the leuprolide levels, XX over to proportion achieved of relugolix the of in relugolix group. than in by Discontinuation relugolix in the men achieved in HERO the days of discontinuation. after of men group study, men higher leuprolide the with suppression a those also PSA faster treatment group treatment reversed half response XX X% Additionally, a day testosterone group. compared compared discontinuation

Finally, lower of HERO group major men to in events in the men cardiovascular group. leuprolide the from compared study, the in adverse had relugolix a Safety Analysis incidence a

cancer. relugolix, men dissatisfied in the research were want Given risk research will with attractive XX% that men the XX% physicians are a patient a the of patients, payers, have cancer, and conducted confident cardiovascular market disease oral attribute treatment a as that approved, In role relugolix. have injection of prostate of of once-daily indicates with I'm if survey prostate an injection. the leuprolide; a cancer men factors pill, men with extremely cardiovascular in more common men significant and standpoint, to-date From market most prostate than XXX extensive of hundreds our with cancer. with prostate rated diagnosed Approximately of not

enrolled and diabetes, smoking name or at In out from of study whether our very fact, cardiovascular in boards. we have a one for factor From age, feedback nine market disease, men obesity, in consistent to research least had few. the hypertension, it be a risk physician HERO ad standpoint, heard XX hyperlipidemia,

clinical survey increased in that its or cardiovascular risk profile. extremely most their For found based of of at patients already for XX% a and to understand prescribe relugolix recent are very indicated disease. likely physicians oncologists, also We've XXX likely they're on urologists medical example,

adverse and was analysis impressed terms of treat needed in particularly indicating both by efficacy, the with suggests benefits Nexus and of that They're payer number economic the XXXX that event presented to one receiving readily to prevent XX injections. patients major clinical understand boards Finally, at versus ad leuprolide AMCP the relugolix research relugolix an payers safety. Meeting, cardiovascular

by of XXX% efficacy on essential XX% first the Approximately of launch second the study, standard physicians that in-office to LUGPAs. new and very profile established as known We have of Our capability cancer. detailing leverage relugolix Salesforce prescriptions believe also medical become prescribers label. LUGPAs large write the U.S. access, the practices, following a with X year-over-year. prescribers. to oncologists Initially, has educate to clinics continues our with advanced grow on will other and be according that relugolix priority to There on and will prostate our approximately approval that establish safety and proportion priority. broad and profile for It multi-specialty the we patient dispensing group multi-specialty to based men our Phase experienced the is were volume potential that to HERO XX,XXX urologists either care this practices, the belonging of majority in approved focus efforts ADT or urology most high

coverage distribution support. Here we're information very our fulfillment, meetings, focusing boards, pricing and deliberate payer Based coverage to and approach year. on the gain taking patients preapproval with key coverage as confident XXXX on in payer the our early continuing payer commercial for decision Part we're and ability contracting, and a throughout increase exchange and commercial starting of ad and first quarter to as patient research, TPM D

third awareness priority launch raise among their treatment Our prostate is options. to regarding patients cancer

we're that, COVID-XX a profile segment and in and attractive administration, oral engaged very very patient actively patients. time research in patients is through relugolix of in The identified will is clinical Frank turn now their that to these the have With strength education. disease to quarter the look a the particularly summary, financial call from of Year. We In seeking to discuss second delivering Frank? to forward launch results. New over early this our to I approaching and position

Frank Karbe

Adele I'll earlier you, and starts our and Thank issued additional on press XX-Q Please the for the year Myovant's you X. today comments our good information. financial highlights in refer remember that release performance morning and to focus quarter my of Form April on fiscal everyone.

in results XX expenses fiscal our quarter G&A represent compared were $XX.X our compared comparable $XX.X readiness for quarter offset and as quarter approximately increased overhead increased million comparable $XX.X The by Phase associated expenses $XX.X September was ended increase to commercial were on which quarter prior-year period. of general stock-based we for $XX.X for million in expenses year So reflects activities, Organization the period. $X personnel-related other to the this upcoming second costs, for of of to Myovant's partially million potential financial million, R&D continue Myovant's a expenses expenses with in were XXXX. potential million spending due quarter the of relugolix. million primarily programs, for completion the commercial X prior-year launches build-out continued The and the preparation decrease of launches. primarily in the Affairs was expenses operating commercial Medical prepare down for the wind Total R&D to compensation. of the the

generated our in the We a per incurred recorded foreign to for the compared loss comparable second quarter loss income line. period. $X a basis, $XX.X currency gain was net also of the XXXX million was other share second XXXX on of in a during quarter our million Myovant that $X.XX quarter net prior-year XXXX. $XX.X in On quarter million in and $X.XX second

build-out June our prostate to declining and expected expenses expect the of hiring driven sales fibroid the to are increase on health sales In to are next the lifecycle possible of year, in that expected trend. capabilities, XXXX as certain in sales similar incremental from expected be oncology our incurred, to year. and of health expenses several expected we FDA's where second forces. expense, spend to commercial levels of The be occur on calendar in upcoming The women's of is by as our women's X, as to close force potential there continue the date December new force are offset this this ahead, completed target be majority hiring our activities our cancer G&A quarter filing next underway deviations be regulatory action of of well hiring is to particularly we uterine XXXX. Looking modest management second and pipeline. at quarters quarter investments could down quarters, as to R&D expenses spend programs winding R&D our by is clinical over

by expense from been amounts approximately capacity quarter through a our wrap-up and to has committed including In August ended of quarterly remaining committed financing facility Dainippon minimize draw commitments, cash XXXX on to Pharma, the to low approximately us. basis cash fund XX, the our position. including shareholder with The we In cost on used. near-term million facility as amount $XXX of currently this September new million. borrowing Let interest portion on fund total to our in we operations. we our loan million Dainippon order a already to the equivalents, Sumitomo our extended a and commitment between Therefore, million me $XXX marketable cash Sumitomo which million available operations securities cash, as that of million, totality, majority that $XXX $XXX Note We to our $XXX in had Pharma, September of sheet. the from $XXX commenting loan our balance deploy XX.

XXXX, first our year, expect increases. by in potentially next of significant launch cash targeting future drug of offset early with we both the middle revenue which as commercial one be anticipated are burn partially and the our Lastly, to second opportunities,

Lynn Now for turn it I'll some back remarks. closing to

Lynn Seely

and tablet is for Frank as in Myovant this uterine we approach in U.S. launches in cancer and the combination an relugolix indication you, XXXX, Thank early the the in potential Adele. indications prostate fibroids relugolix In of summary, exciting mid-XXXX. time

Our focus important these options to patients. is and successfully executing on bringing these squarely launches, therapeutic

We upcoming in cash data months, and financial multiple we're product potential launches. regulatory committed million upcoming with the XX approximately a have financing and clinical next and of resource appropriately in to strong position $XXX milestones

for Thank rights I business get to Myovant look franchise, the work the we your development what turn now ahead full done Myovant. Ryan I'll for extremely proud and you it us all to is maximum providing forward for U.S. Q&A begin to to team this Finally, the have opportunity. relugolix with to optionality by attention. over the for of point, session. I'm

Ryan Crowe

for regulatory questions? for we operator, questions discussions regarding now interactions. questions, up before be responding given One regulatory with Lynn. that please poll we our we'll not you, any can it With said, authorities, our open to Thank note ongoing

Operator

Instructions]. Thank you. [Operator

Jason Our Securities. first question with comes from Butler JMP

Your is open. now line

Jason Butler

Hi, thanks progress. the on questions for taking the and congrats

on Just cancer the a prostate couple launch.

give more volume what those other First, details be of between you might split about docs you docs be what us proportion initially the D market on versus focused between a give those of commercial XX,XXX and you Part high in centers Thanks. then coverage? you'll the can on reimbursement any mentioned terms breakdown and multi-spec us the prescribers, can just of and

Lynn Seely

why Adele, you those Jason. questions? Thanks, don’t take

Adele Gulfo

Sure, you correctly. heard I if

will substantial urology a business who question? piece with we was LUGPAs in clinics, question first as the high whether of what prescribing expect be The multi-specialty to XX,XXX majority they I prescribers, call, second the or large that's our the from clinics, was medical oncology, today. volume because very And the of those your regard that mentioned is ADTs doing the come

Jason Butler

how between Part Just breaks commercial market coverage? and the out D

Adele Gulfo

would our It's XX% to approximately, patients they'll commercially of I expect we say be business, XX:XX, insured. right, commercial be

The that affordable there they're to have them plans. enable low assume let's patients, of They're subsidies; Medicare on income that on patients From other note Medicare about important proportion employer out a that half have be group copay. they Medicare. either plans may have will those They it's to half may are waiver of plans. more

or feel have plan of that So other that have there's a XX% affordable nice enable we to them chunk a piece access. will of will that Medicare

Jason Butler

Thanks Okay, for taking the great. questions.

Lynn Seely

please. question, next Jimmy,

Operator

you. Thank

Leerink. from Fadia Our next with question comes Ami SVB

line is Your now open.

Ami Fadia

question. Thanks morning. I good couple. the have for a Hi,

point. and with you've inspection with review labeling with pre-approval sort any regulatory regards at a FDA of to regards began about to discussions your for progress if cancer. prostate Can you the Firstly, talk this any just around

would in dollars, narrow stands. well some In can tens And have one Lupron, relugolix cancer kind about you on where us extended of philosophy one pricing down you but health? prostate if hand, where me as try Lupron pricing thousands the more have we prostate Secondly, give cancer on there. I in think then in price for it's you course, women's color us, of let so to both as of here. then and your And of question, [ph] net pause can

Lynn Seely

questions. thanks Well, sure Ami the for

question with regulatory begin your me about approval. Let

this action approval the very during stated date, XX, FDA call track the clearly on December conference we PDUFA that think I date, we're for XXXX.

regulatory obviously, we're interactions. that with progress to further made. pleased not we're comment we've So But going on the ongoing

presented New I question. value compared particularly the to profile should that lower the We that acquisition with based and In X based value think patients. the study patients, relugolix the our with Journal. that think, price, safety cardiovascular in believe and respect at case brings with on relugolix medicine I relugolix published appreciate events, expect England to has to incidence wholesale I to of premium of to of new And upon price in our on the the been be they leuprolide, cost we pricing a Lupron. the Phase bring efficacy based

Ami Fadia

a Got it level of it, helpful. is point give that too at quantify or color? much okay. That's to premium Can this you, early how of

Lynn Seely

of about approval. Yes, more we'll I you. the Thank think be talking around price time

Ami Fadia

I to and in then the could the context to about we ask getting relugolix it treated first launch get and as patients get relugolix product also ramp first, and of whether regards payers with coverage might from with sort Thanks. adoption, us get Where takes the product? for terms ramp. initial If prescribed practices getting what be you just Okay. patient the just might adopt time the to also on see put then the think and then it to do launch the in with Adele, and stage question a of disease initial of which

Lynn Seely

Adele?

Adele Gulfo

into question, lot Yes, thanks. Thanks A that. for Ami. the packed

So I want that, very about would excited product first, the say physicians to are reiterate I profile.

XX%, -- very our I were over prescribe on most said, relugolix likely profile. extremely in is As clinical to recent the survey based likely there or

England Journal that this So because very among we're could pre-launches we stage a parameter at is There's publication. New excited. high early atypical, of bit little be also and our have physicians, it awareness that

from So physician. those two the things

know patients versus time that prefer oral a once-daily that men injection. in a truly also patients We an

medical who in environment. very only the community very are adept then knowledge at XXX% be selling will hiring virtual urology I And there marketplace, of oncology, salesforce, this as the mentioned, think we're from we as well. patient but So have rep, who not and interest experienced our reps

the done area rigorous have and as job representatives we've therapeutic expertise as well getting the a sales screened as well. who in technology expertise So very

factor on we together, I'll together. all with it those for very leave as community physician we the track as ramp-up coming we’ll that. when a -- the have at So well we're feel comfortable patients a that

Lynn Seely

all Adele. that time. Thanks, we add takes might that coverage I know And just to that

expect And is will ramp yes, the it's time coverage. preparing have going revenue which to And within. we pandemic that to reflect that so we take that to a COVID there launch going on get been

surprise no consider. but to that's for injection. men, to care option say is I'll important fact the to standard So an an that we're them that requires oral into where that's offering current offset the for going by the of go clinic be

we to we're as again, So can prepared pandemic this into launch be. as COVID

Ami Fadia

you. Thank

Lynn Seely

Operator, next question?

Operator

Thank you.

next comes Bansal Mohit from Our with Citi. question

Your now line open. is

James Shin

what good question I This cancer the offices? guys us is you're ground like you from and PDUFA given right for Mohit. a more is urology Hey, for had around tell the you seeing on can morning. on for in the corner James mentioned, the Adele, private prostate so pandemic,

Lynn Seely

Adele?

Adele Gulfo

can urology on private a you we're that, just seeing? the be From more clear offices, what little bit

James Shin

at I right still five-year Are to guess doesn't they capacity, open to it and patients be urology they even like, actually Well, now? operating have are they full offices.

offices so seeing sort urology What open, broader at it there you are make far? of these are just XX% widely centers Let's capacity? these are

Adele Gulfo

say would a from it's I They're growing. months ago. couple where of it was growing

back picking oncologists the is up. been have community now pretty the Now, And also stable. urology

this hear represent in-person, sales And And access the from standard are feel of the relugolix. product terms that we profile you that of what have perspective. want a is about is there new not but doctors a a the same access care. we interested we're to could in virtual They product very as whenever actually to there's So seeing in representatives of is like it. said

had go as So that doing physicians have we we've attend diligence. meetings, to we're questions having, boards, to answer no our to we're to trouble securing ad

for and urology important because really oncology practices a So confident from we're our them. hearing to product pretty that we the practices will open be the represent representatives

James Shin

could one was if on, much then going may, fibroids more at mineral I the you it. to to the itself. Got filing I FDA, from you if know give And uterine least? aren't status for bone the share But guys density updates too submitted

Lynn Seely

Juan Camilo?

Juan Camilo Arjona

I data from so you. as initial one-year included for thank that History fibroids, bone as uterine mineral our fibroid. our Yes, study density for Natural patients NDA, can the well the with in we uterine confirm one-year data

James Shin

it That's appreciate end. Got from my it, it.

Lynn Seely

Thank you.

Next question, Jimmy?

Operator

Thank you.

with question next JP comes Eric from Our Morgan. Joseph

line now is open. Your

Eric Joseph

Hi, for split guess, first prostate switch opportunity Is in good a there or and initial about meaningful currently I morning. the questions. other with thinking Thanks ADT, taking Lupron is uptick cancer. Thanks. then for the coverage the rate therapy? -- different highlighting split in should segments? a secondly, Depot product, we -- thanks D And then between those cover in either on product different for commercial. Part anticipate here between and adoption Is there adoption

Lynn Seely

Adele?

Adele Gulfo

bid coverage on have for the cycle, our Yes, of exception because expect to information medical we formulary patients are that there with by Medicare. June processes about adoption. of rate so for Medicare realizing would start coverage year, I'll the also Medicare are Yes, of next regarding that

that's the that So Medicare will on front. come,

would during front, as remarks, the as coverage prepared seeing of the expect quarter we early first to as the next said, On start commercial I year.

Lynn Seely

question both relugolix patients include advanced And then second that in and terms for your about naive prostate will is therapy. who on currently of appropriate cancer the again, a think men spectrum treatment I patients as well are opportunity patients broad of for we as relugolix with believe with

Eric Joseph

for question. Okay, taking Thanks the great.

part I actually, is strategy of I thanks. directing importance detailing DTC treatment of launch of for on just can think one guess, the to cancer, Lynn, sort relugolix speculate if could extent decisions. Just prostate the I you consumers longer-term and in follow-up to what

Lynn Seely

Adele? Sure.

Adele Gulfo

I importantly, that our educated What question. understand physicians the the very profile for on again thanks it. we they Yes, say ensure have most product to are would and well is,

wanting physician drive to large into do in disease engaged from clear the are where the we said, know that their and very that is is do constantly awareness research an and more So identifiable and we adequately segment there not last of is treatment very prepared. men With actively options. to about want seeking patients their education a thing office appreciate our who're pretty market and

time, we So a are we'll reach caregivers information. appropriate caregivers at who very seeking who their the because their know these do patients programs and and lot the we are adequate ensure these that also actively men to have daughters of

what say place can in population. broadcast conjures efficient DTC we And big in are this for TV, that a reach not is There segment. when we very have plans lot However, think that television. ways this right there's patient needed which up things, of the you That's those now. we are

Eric Joseph

got Thanks for That’s question. it. taking helpful. Okay, the

Lynn Seely

Eric. Thanks,

Next please. question,

Operator

Thank you.

Our Brian Baird. next comes Skorney with question from

Your open. now line is

Brian Skorney

for Hey, taking you good morning. questions. the Thank

Just on the is I pandemic, difficult terms prostate warehouse therapy if was terms I patients any long annual next you. guess terms once be we in you cancer And had of in sort even cancer I on segment? your have Thank what rebound it's through how look of months? Lupron, to drug of much of effect through the in the sort guys better when starts. a sort then that expectations expecting to just prostate we any are or in in and at wondering average? a new couple couple get data of be should track how a of new if And, you maybe dipped will of of kind indication on the durability, launch, through castration of And terms impending starts

Lynn Seely

Adele? Sure.

Adele Gulfo

Yes.

around question on big about first well What the the XXX,XXX is, that research, data ADT. would just secondary indicated and from me as as we data. starts coming polls patients, new let say have I the So

year-over-year. With coming I will forgot. approximately patients I approximately XXX,XXX new sorry, we XXX,XXX That's data have. our to be sure information on As I what we've around making on regard on estimating that those the forecasting XXXX what numbers. that's starts prepared I been -- your was said in had question. there's And I'm remarks, your What in therapy we're question? second was the with

Brian Skorney

a XQ, dips kind of data durability? late to and terms some was decline starts? pandemic? expecting It to you then XQ in just effect, Yes. increase expect separate delays in warehouse in on expect of the Sure. what you patients? like terms any are in sort would any of new Would due substantial the given starts we of And maybe even And following question,

Adele Gulfo

this For about durability, as therapy. think backbone we a always

this other get for So be they on as as not continue men they even years, months will therapies. to --

durability. that's the about data, here's annually. With actually what would X% -- say continue -- I regard piece the haven't, grow is we've that's to we to on -- this market So, seen market

We haven't seen dips.

comment would what And relative it's growth the say $XXX,XXX the for So is X% to year-over-year a best I would market we ADT data with available I about that's, the that's say today. can a large that's that, prescriptions.

Brian Skorney

Okay, thank you.

Lynn Seely

Brian. Thanks,

Next question, please.

Operator

Thank you.

Nadeau with Company. next comes and Cowen question Our Phil from

Your line is now open.

Phil Nadeau

pipeline. Good the Couple cancer morning. Congrats on progress. on questions prostate on relugolix the actual then one of

the trends cancer, one trends idea any for men, those intermittent relugolix therapy in on Do intermittent place First want number of therapy for physicians therapy. the -- that thought on who intermittent on have either the any on fit or figures in are product? of who adoption is and prostate the would currently you perfectly of in be men have to

Lynn Seely

thanks. Sure,

men But had is spectrum cancer. therapy. many versus So after of is days men men advanced for injection. may normal as of with that therapy opportunity prostate discontinuation an stopping men recall is three relugolix, after within X% range the we who months have on testosterone the XX of to you appropriate which And that broad to their last leuprolide, it after of XX% relugolix recovery we the with of earlier, particularly absolutely the attractive said profile believe true relugolix discontinue

And which so receiving that are grow their of that has therapy men have therapy, the is been to XX% to holidays who this drug may for after we intermittent something men about can over controlled. XX% and And is PSA could intermittent estimate today be particularly opportunity basically attractive time.

Phil Nadeau

now? in a Perfect, the helpful. to follow-up on in safety completing that's you benefit, study second the saw CV that's Then to very on signal one the do relugolix trends for maybe that do any the particular, you have CV safety specific study similar

Lynn Seely

that question. a we're the made absolutely decisions that's at And we've this but looking time. it's feasibility, any considering at something Yes, great and about not

Phil Nadeau

any then next recent question What XXXX advancing you to your MVT-XXX. have a Do plans And study? just is actually last that? on start plans Great. for in are most

Lynn Seely

our squarely MVT-XXX infertility. you about female a about novel clearly Yes. We're have At been that you'll expect XXXX. kisspeptin for be hearing know; that But it's point more developing launches. on as agonist focused in and MVT-XXX excited very we we this time, we’re in

Phil Nadeau

taking for questions. Thanks Great. my

Lynn Seely

question? next Operator,

Operator

next you. question our And Sachs. Thank comes Choi from with Goldman Paul

line is Your now open.

Paul Choi

in GnRH Thank the of of medical for frequency utilization you. you progress. urologists so current is cancer for prostate do products of in one and oncologists Either LUGPAs the Good about maybe threading you between just Lynn needle, your don't maybe Adele, isolate what morning there you population terms how and talk can congrats the launch? promoting on or think the about and all

Lynn Seely

want Paul. do you start? thanks, to Sure, Adele

Adele Gulfo

are rate sales perhaps going for Sure. are our there higher from also high are in advanced of one prostate and that us. to high other. both the We distancing see And those prescribers very We target from They're -- cancer. targeting be coming they're high don't plans see slightly both. oncologists volume this office. volumes that are very to adequately medical our with also men urology prescribers that both season. But be our there's believe populations we'd a for of the audience And important prescribers educate a for important reps the I

Paul Choi

feedback changes about have any be XX% a data, and any very prescribe Adele. they're to questions. that utilization, market would you Thanks, you there? how with as prior the thinking our that, Thank earlier, research just it, received data, updated referenced follow-up just for maybe to you survival regard taking can may maybe and much suggesting be you from on the -- willing And -- the of would HERO physicians then just willing physicians provide survival your post

Lynn Seely

castration Thank between on and the outcomes you. relugolix can that resistance just I comment similarly leuprolide. and free presented recently data was survival demonstrated

what is relugolix get treatment, actually physicians they can reassured we leuprolide, comparable. didn't outcomes. were over are with benefits cardiovascular the I data of of show found think we the that incidence that And events comparable the superiority While including lower the

really haven't about seen so our And research or in interest. utilization differences we any

So, question. operator, I the that's believe last

Operator

in no the this I'm at showing further questions time. queue

Lynn Seely

you. thank Okay,

heard, some closing me just remarks. make let As you've

us you Myovant. continued before to indications. heard, Stay updating strategy in transformational opportunities forward I to in your launch are progress We you for As you've for prostate future expected highly for cancer the our in to safe us the two are be next by truly and our look XX and today engagement and Myovant products remain on as months three Thank to health. and just we with calls. and motivated XX in joining all healthy. women's look confident

Operator

Ladies and Sciences gentlemen, fiscal participation. earnings you for Myovant your this XXXX quarter second concludes call. Thank

disconnect. now You may

Myovant Sciences (MYOV) 12 Nov 202020 Q2 Earnings call transcript